Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
A PROSPECTIVE EUROPEAN VALIDATION COHORT FOR STEREOTACTIC THERAPY OF RE-ENTRANT TACHYCARDIA (STOPSTORM)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Italy,Germany,Germany,Germany,Germany,Germany,Germany,Spain,Italy,Spain,Italy,Spain,Italy,Switzerland,Switzerland,Poland,Switzerland,Poland,Czechia,Czechia,Netherlands,Netherlands,Netherlands,Netherlands,Netherlands,Netherlands,Denmark
Call: New interventions for Non-Communicable Diseases (H2020-SC1-2020-Two-Stage-RTD, 2020)
Start date: 2021-05-01
End date: 2027-04-30
Duration (months): 72.0
Total project cost (EUR): 7161436.5
EU funding (EUR): 7161436.5
Participants: 31
Project status: SIGNED

Ventricular tachycardia (VT) is an unpredictable and potentially deadly condition and should be promptly treated with catheter ablation and medication, before irreversible and potentially fatal organ damage follows. Unfortunately, this combination of treatments does not prevent VT reoccurrence in 30-50% of VT patients and while they can undergo multiple invasive ablations, technical difficulties or refusal of the patient can lead to a lack of effective treatment options. A promising novel, non-invasive treatment option for VT is stereotactic arrhythmia radioablation (STAR). Besides being non-invasive, STAR can also be used to reach locations that are inaccessible for catheter ablation, which may potentially improve effectiveness of overall VT treatment. Small scale first in men/early phase trials have been performed for STAR, providing proof-of-concept for clinical safety and efficacy. However, patients with recurrent VT are not a homogenous group and each center deals with different inclusion criteria, imaging and/or target definition. Many questions remain and the available studies lack the power to clinically validate the approach and prepare for late stage phase III trials. The STOPSTORM consortium sets out to consolidate all current and future European efforts to clinically validate STAR treatment by merging all data in a validation cohort study, standardising pre-treatment and follow-up, in order to collect the data sets and statistical power needed to unanimously establish clinical safety, efficacy and benefit for STAR. The STOPSTORM consortium also sets out to refine protocols and guidelines, determine volumes of interest, define and model the optimal target region and target dose, also in relation to surrounding healthy tissues (i.e. organs at risk) and determine which patient population and underlying cardiopathies respond best to STAR. By doing so the STOPSTORM consortium paves the way to consensus and future late stage clinical trials for STAR.

Keywords: ventricular tachycardia,cardiomyopathy,cardiac radioablation,stereotactic ablative radiotherapy sabr,stereotactic body radiation therapy sbrt,electrical storm
An innovative dental implant with osteoinductive properties by means of bioactive sol-gel coating (SolDent)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Nanotechnologies
Action type: SME instrument
Countries involved: Spain
Call: Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs (H2020-SMEINST-1-2014, 2014)
Start date: 2014-10-01
End date: 2015-03-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

In the treatment of edentulous patients with dental implants, there are usually strict patient selection criteria based on well-recognised risk factors that are associated with poor bone-forming activity, such as diabetes, smoking or metabolic bone disorders. Therefore, many patients remain untreated with dental implant clinical practice. Additionally, the expectations of both surgeons and patients of shortening the recovery phase of the dental implant treatments have led Ilerimplant –a well-recognised Spanish manufacturer of dental implants with an excellent worldwide network of distributors– to develop an innovative osteoinductive dental implant by means of a biodegradable coating. The osteoinductive properties, one of the most desired in the last generation of dental implants but not reached yet, have been obtained by a bioactive organic-inorganic hybrid material specially tailored for this purpose by a sol-gel coating process. Ilerimplant’s overall goals with this innovation project are to industrialise and introduce in the market a new generation of osteoinductive dental implants based on this sol-gel coating (SolDent). Taking into account that the global dental implant markets are continuously growing and that SolDent will be the unique product in the market with effective osteoinductive properties, Ilerimplant expects to make a qualitative leap in market shares and sales with an eminently European and international approach. Firstly, we will conduct a practical and economic feasibility study in Phase 1 in order to assess the industrialisation process, regulatory issues and commercialisation strategy, ending with the elaboration of a comprehensive business plan. In Phase 2, we will address industrialisation and clinical trial in order to achieve full commercialisation during Phase 3.

Keywords: dental implant,sol gel,bioactive,coating,osteoinduction,edentulism,bone generation
From longitudinal proteomics to dynamic individualized diagnostics (DynaOmics)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Finland
Call: ERC Starting Grant (ERC-2015-STG, 2015)
Start date: 2016-06-01
End date: 2022-05-31
Duration (months): 72.0
Total project cost (EUR): 1499869.0
EU funding (EUR): 1499869.0
Participants: 1
Project status: CLOSED

Longitudinal omics data hold great promise to improve biomarker detection and enable dynamic individualized predictions. Recent technological advances have made proteomics an increasingly attractive option but clinical longitudinal proteomic datasets are still rare and computational tools for their analysis underdeveloped. The objective of this proposal is to create a roadmap to detect clinically feasible protein markers using longitudinal data and effective computational tools. A biomedical focus is on early detection of Type 1 diabetes (T1D). Specific objectives are: 1) Novel biomarker detector using longitudinal data. DynaOmics introduces novel types of multi-level dynamic markers that are undetectable in conventional single-time cross-sectional studies (e.g. within-individual changes in abundance or associations), develops optimization methods for their robust and reproducible detection within and across individuals, and validates their utility in well-defined samples. 2) Individualized disease risk prediction dynamically. DynaOmics develops dynamic individualized predictive models using the multi-level longitudinal proteome features and novel statistical and machine learning methods that have previously not been used in this context, including joint models of longitudinal and time-to-event data, and one-class classification type techniques. 3) Dynamic prediction of T1D. DynaOmics builds a predictive model of dynamic T1D risk to assist early detection of the disease, which is crucial for developing future therapeutic and preventive strategies. T1D typically involves a relatively long symptom-free period before clinical diagnosis but current tools to predict early T1D risk have restricted power. The objectives involve innovative and unconventional approaches and address major unmet challenges in the field, having high potential to open new avenues for diagnosis and treatment of complex diseases and fundamentally novel insights towards precision medicine.

Keywords: computational biomedicine,systems biology,longitudinal data analysis,molecular networks,biomarker,statistical data mining,predictive modeling,clinical sample material,type 1 diabetes
Flexible FE/BE Sensor Pilot Line for the Internet of Everything (IoSense)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Theme: Public-private partnerships
Destination: Electronic Components and Systems
Action type: Innovation actions
Partnership: ECSEL (Art-187)
Countries involved: Austria,Austria,Austria,Germany,Germany,Germany,Spain,Austria,Spain,Spain,Germany,Austria,Slovakia,Belgium,Netherlands,Netherlands,Netherlands
Call: Semicondutor Process, Equipment and Materials (H2020-ECSEL-2015-2-IA-two-stage, 2015)
Start date: 2016-05-01
End date: 2019-04-30
Duration (months): 36.0
Total project cost (EUR): 64237980.13
EU funding (EUR): 14483029.61
Participants: 34
Project status: CLOSED

The EU has set the stage to empower semiconductor manufacturing in Europe being one of the key drivers for innovation and employment and creator for answers to the challenges of the modern society. Aim of IoSense is to boost the European competitiveness of ECS industries by increasing the pilot production capacity and improving Time-to-Market for innovative microelectronics, accomplished by establishing three fully connected semiconductor pilot lines in Europe: two 200mm frontend (Dresden and Regensburg) and one backend (Regensburg) lines networking with existing highly specialized manufacturing lines. Focus is the availability of top innovative, competitive sensors and sensor systems “Made in Europe” for applications in Smart Mobility, Society, Energy, Health and Production. Today competitors are already involved in the development of sensor systems for applications in the emerging “Internet of Things”. But there is a significant gap between those forces and the capabilities to bring ideas into the high volume market fast enough. IoSense will close this gap by providing three modular flexible pilot lines being seamless integrated in the IoT value crating networks and ready to manufacture each kind of sensor system prototypes. IoSense will increase the manufacturing capacity of sensor/MEMS components in the involved pilot lines by factor of 10 while reducing manufacturing cost and time by 30%. IoSense is designed to enable focused development work on technological and application oriented tasks combining with market orientation. “Design to Market Needs” will be accomplished by customer involvement, embedding all required functionality besides sensors. Finally, the time for idea-to-market for new sensor systems is intended to be brought down to less than one year. As a result, semiconductor manufacturing will get a new boost in Europe enabling the industry with competitive solutions, securing employment and providing answers to the upcoming challenges in the IoT era.

Keywords: pilot line,sensors,sensor systems,semiconductor manufacturing,frontend,backend
Arctic Research Icebreaker Consortium: A strategy for meeting the needs for marine-based research in the Arctic (ARICE)

Framework: Horizon 2020 — Excellent Science
Programme: Research Infrastructures
Theme: Research infrastructures
Destination: Integrating activities and infrastructures
Action type: Research and Innovation actions
Countries involved: Spain,Italy,Iceland,Germany,Finland,Norway,Poland,Sweden,France,France,United States,Denmark,Canada,United Kingdom
Call: Integrating Activities for Starting Communities (H2020-INFRAIA-2017-1-two-stage, 2017)
Start date: 2018-01-01
End date: 2022-12-31
Duration (months): 60.0
Total project cost (EUR): 5996565.5
EU funding (EUR): 5996563.75
Participants: 17
Project status: CLOSED

The recent changes of the Arctic and the increased economic activity in the region have triggered a demand for accurate sea-ice and weather predictions, for information on the status of the Arctic Ocean, and for complex predictions of future scenarios. To address these issues of particular environmental and societal concern and to develop policy recommendations for a sustainable usage of the Arctic Ocean and its resources, the Arctic science community needs world-class research icebreakers (RIs) to access the ice-covered Arctic Ocean. The current shortage of availability of RIs and a not optimally coordinated polar research fleet impedes Europe’s capacity to investigate this region. There is thus an urgent need for providing European researchers with better RI capacities for the Arctic. ARICE aims at reaching this goal with the existing polar fleet by: 1) Networking ARICE will develop strategies to ensure the optimal use of the existing polar research vessels at a European and international level, working towards an International Arctic Research Icebreaker Consortium which will share and jointly fund operational ship time on the available RIs. 2) Trans-national access (TNA) ARICE will provide TNA to six key European and international RIs for European scientists, based on scientific excellence of submitted proposals: - PRV Polarstern, Germany - IB Oden, Sweden - RV Kronprins Haakon, Norway (under construction, to be operative in 2017) - RRS Sir David Attenborough, United Kingdom (under construction, to be operative in 2018) - CCGS Amundsen, Canada - RV Sikuliaq, United States of America 3) Joint research activities ARICE will improve the RIs’ services by partnering with maritime industry on a “ships and platforms of opportunity” programme and by exploring into new technologies that will lead to an improvement of ship-based and autonomous measurements in the Arctic Ocean. ARICE will implement virtual and remote access of data via an innovative 3D Virtual Icebreaker.

Keywords: icebreaker,arctic research,international cooperation,trans national access
Massive Gravity and Cosmology (MassiveCosmo)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Universe sciences
Panel description: Astro-physics/-chemistry/-biology; solar system; planetary systems; stellar, galactic and extragalactic astronomy; cosmology; space sciences; astronomical instrumentation and data
Countries involved: United Kingdom
Call: ERC Consolidator Grant (ERC-2016-COG, 2016)
Start date: 2017-05-01
End date: 2022-10-31
Duration (months): 66.0
Total project cost (EUR): 1975829.0
EU funding (EUR): 1975829.0
Participants: 1
Project status: SIGNED

The ambition of this research program is to challenge the nature of gravity, provide an alternative to dark energy, and pave the way towards a potential resolution of one the most tantalizing problems of physics today: The Old Cosmological Constant Problem. As General Relativity celebrates its centennial, its predictive successes and its status as our most elegant theory of gravity are incontrovertible. Nevertheless, while the recent discovery of the late-time acceleration of the Universe is in perfect agreement with observations, the 120 orders of magnitude discrepancy between expectations and observations is one of today's most challenging puzzles and may be the sign of new physics to uncover. This conundrum has driven the development of dark energy models as alternative sources for acceleration, but many of them suffer from a similar discrepancy and require an unnatural tuning of their parameters. Despite decades of attempts, the Old Cosmological Constant Problem remains yet unsolved. This program proposes a distinct direction to address this problem and to explain the acceleration of the Universe where the graviton, the particle carrier of gravity, has a mass, or is effectively massive. Not only will this open a new panorama for cosmology, it will also answer the fundamental question of the nature of the graviton. Signatures and constraints will be derived through astrophysical and cosmological probes. While striving to address these fundamental challenges, the program will also elucidate new aspects of massive gravity by establishing its theoretical viability and embedding as an effective field theory. These developments will feed into new breakthroughs that have recently emerged from massive gravity. As major missions and experiments are underway to probe dark energy and to detect gravitational waves, there is no better time to question gravity at the fundamental level, to provide alternatives to dark energy and to determine their unique signatures.

Keywords: gravitation
Perspectives For Future Innovation in Tendon Repair (P4 FIT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Joint Doctorates
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Austria,Germany,Italy,Italy,Finland,United Kingdom
Call: Innovative Training Networks (H2020-MSCA-ITN-2020, 2020)
Start date: 2021-01-01
End date: 2024-12-31
Duration (months): 48.0
Total project cost (EUR): 4043040.48
EU funding (EUR): 4043040.48
Participants: 6
Project status: SIGNED

Innovation in tendon medicine is a promising frontier to respond to the urgent societal/economic healthcare demand determined by the worldwide growing incidence of tendinopathy. Perspectives For Future Innovation in Tendon repair (P4 FIT) fosters to build a new generation of 15 early stage researchers with adequate skills to explore non-conventional therapeutic and diagnostic solutions by exploiting the technological advances in nanomedicine. The University of Helsinki brings together world-renowned academic and non-academic EU institutions, covering most of the basic and technological disciplines of the fields to launch a unique EJD. The inter-disciplinary, inter-sectoral, and international high quality educational environment will booster innovation-driving training and research leadership grounded in excellence for widening success in P4 medicine (predictive, preventive, personalized and participatory), promoting tendinopathy resolution. P4 FIT will encourage cross-disciplinary working under the coordination of human and veterinary orthopedics addressing innovation and R&D facilities to combine multidrug nanovectors/nanotheranostic devices with tissue engineering. The translation of innovative nanodevices carried out on integrated pre-clinical and vet/human clinical settings will produce solid evidence-based datasets able to reduce fragmentation still limiting the impact of biomedical discoveries and to offer a unique opportunity for identifying new predictive biomarkers through the use of AI and deep learning data analysis. Working across disciplines and sectors, P4 FIT will foster ESRs to be creative, critical, autonomous intellectual risk takers at the frontiers of research with the R&I mind-set necessary for thriving careers. P4 FIT will allow to fill the EU gap in tendon healthcare, building up a generation of researchers able to develop nano-based biomedical devices by integrating biology advances to technology innovation, and to computational revolution.

Keywords: nanovectors,nanotheranostics,multidrug delivery,nanoparticles,nanomedicines,tendon regenerative medicine,stem cells,bioactive molecules,immunomodulation,data analysis,biosensors,bioimaging
effIcieNt Small scale uniT for distributed heAt and hydrogeN generaTion (INSTANT)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Products and processes engineering
Panel description: Product and process design, chemical, civil, environmental, mechanical, vehicle engineering, energy processes and relevant computational methods
Countries involved: Italy
Call: Call for proposals for ERC Proof of Concept Grant (ERC-2020-PoC, 2020)
Start date: 2021-07-01
End date: 2023-03-31
Duration (months): 21.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: SIGNED

The project task is the development and validation of an efficient catalytic fuel processor as the key component of small scale units for combined heat and power (CHP) generation in residential applications, based on hydrogen-fuel cells and fed by natural gas, air and water. A critical issue of these devices is the intensification of the heat supply in the compact methane steam reformer where hydrogen is generated. To this purpose we exploit the findings from my ERC AdG project INTENT, developing a reformer design based on thermally conductive cellular structures packed with catalyst microparticles. As demonstrated already in INTENT by lab scale tests, the flow independent conductive heat exchange mechanism enables a highly effective power supply to the endothermic catalytic reaction even in the case of low and fluctuating flow rates, as typical of these compact units. The INSTANT project aims at testing this novel configuration of the fuel processor at a semi-industrial scale (TRL5). Indicators which will be evaluated during the test sessions include: 1) the H2 productivity for a given catalyst load (target = +30%); 2) the start-up time to full load (target = -30%); 3) the response time to a load change (target = -30%). Based on the experimental outcomes, INSTANT will also assess the potential for reducing the footprint of the CHP unit, the system volume being currently one of the main constraints for domestic CHP applications, as well as the overall production cost, including life-cycle costs. If successful, INSTANT will pave the way to a new generation of CHP systems based on hydrogen fuel cells, to be used in residential applications and, in perspective, in hydrogen refueling stations for fuel-cell vehicles, thus contributing to the decarbonisation of the EU energy system.

Keywords: hydrogen,distributed heat and power generation,fuel processor,methane steam reforming,open cell foams,process intensification